Apart from MSI, there are other classification systems to stratify patients, such as consensus molecular subtypes, tumour mutation burden (TMB), PD‐1/PD‐L1, CTLA‐4 and tumour immune microenvironment.3 This evidence concerns the gene CD274 and neoplasm.